Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll Biopharma Begins Phase 3 VELOS-4 Trial for Tanfanercept in Dry Eye Disease
Details : HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.
Product Name : HL036
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2024
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Altos Biologics Files for Approval of Aflibercept Biosimilar
Details : ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Product Name : ALT-L9
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.
Product Name : HL036
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : Tanfanercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Product Name : ALT-L9
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : HLB Group
Deal Size : Undisclosed
Deal Type : Acquisition
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
Details : Acquisition of GtreeBNT by HLB Group, would speed up the clinical trials currently in progress and allow the company to focus on new drug approval. RGN-259 will remain a priority for the company.
Product Name : RGN-259
Product Type : Protein
Upfront Cash : Undisclosed
September 27, 2021
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : HLB Group
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
Details : Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness.
Product Name : SB11
Product Type : Antibody
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Samsung Bioepis Unveils Final Results of Phase 3 Clinical Trial for SB11
Details : SB11 is the sixth biosimilar product and the first eye disease treatment that Samsung Bioepis developed after three autoimmune disease treatments (SB2, SB4, SB5) and two tumor disease treatments (SB3, SB8).
Product Name : SB11
Product Type : Antibody
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : If approved, SB11 will add to the biosimilars portfolio developed by Samsung Bioepis and commercialized by Biogen, including three widely prescribed anti-TNF biosimilars in Europe; BENEPALI™, IMRALDI™ and FLIXABI™.
Product Name : SB11
Product Type : Antibody
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RegeneRx Joint Venture GtreeBNT Expects to Complete Phase 3 Dry Eye Trial in November 2020
Details : ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after two weeks of administration in 700 subjects with dry eye syndrome.
Product Name : RGN-259
Product Type : Protein
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Timbetasin Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar
Details : The randomized, double-masked, parallel group, multicenter study will compare SB15 and reference Eylea on safety, efficacy, pharmacokinetics, and immunogenicity.
Product Name : Opuviz
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable